Latham & Watkins Advises HilleVax on Pricing of Public Offering of Common Stock. HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing...
HilleVax’s €100 Million Common Stock Public Offering
HilleVax’s $200 Million Initial Public Offering
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...